Single-dose genetic medicine halts the progression of ALS and frontotemporal dementia in mice

Neuroscientists at Macquarie University in Australia have developed a single-dose genetic medicine that has been proven to halt the progression of both ALS and frontotemporal dementia (FTD) in mice – and may even offer the potential to reverse some of the effects of the fatal diseases.

Risk adjusted net present value: What is the current valuation of F. Hoffmann-La Roche’s Basmisanil?

Basmisanil is a small molecule commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Dup15q Syndrome.

November 20, 2023

USMLE April Fools! What ‘Grey’s Anatomy’ Gets Right; No Red Scrubs in the OR

The following contains links to social media websites including X, TikTok, Instagram, Facebook, and LinkedIn. “Breaking: USMLE has introduced 4 new exams,” said an April

April 5, 2024

Generative AI and Healthcare: Pragmatic Considerations for Proof of Concept Frameworks

Rob Bowman Operating Partner Technology Strategy Services, Healthcare at CXO Partners In pure technology terms, there is no better example of an idealized solution in

October 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.